The effect of Bifidobacterium triple live bacteria on children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia and its influence on intestinal mucosal barrier and prognosis
10.3760/cma.j.cn115455-20241011-00861
- VernacularTitle:双歧杆菌三联活菌治疗支气管哮喘伴肺炎支原体肺炎患儿效果及对肠黏膜屏障和预后的影响
- Author:
Tiantian HU
1
;
Teng ZHANG
1
;
Hefen HU
1
Author Information
1. 济宁医学院附属医院儿科，济宁 272000
- Publication Type:Journal Article
- Keywords:
Bronchial asthma;
Mycoplasma pneumoniae pneumonia;
Child;
Bifidobacterium triple live bacteria;
Prognosis
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(12):1074-1078
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the adjuvant treatment effect of Bifidobacterium triple live bacteria on children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia. Methods:A total of 136 children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia admitted to the Affiliated Hospital of Jining Medical University from January 2021 to September 2023 were prospectively selected as the study subjects. All the children were given intravenous azithromycin infusion treatment. After the temperature returned to normal, symptoms were reduced, and intravenous infusion treatment was stopped, they were divided into two groups according to random number table method. The control group (68 cases) received montelukast sodium tablets and azithromycin, and the observation group (68 cases) received Bifidobacterium triple live capsule oral treatment on the basis of the control group, both groups continued to use the drug for 2 weeks. The treatment effect, improvement of lung function index and intestinal barrier function index and quality of life assessment were observed in the two groups. Results:The total effective rate in the observation group was higher than that in the control group: 94.12%(64/68) vs. 82.35%(56/68), there was statistical difference ( χ2 = 4.53, P<0.05).After treatment, the forced vital capacity and forced expiratory volume in the first second in both groups were increased, and the observation group were higher than those in the control group: (2.55 ± 0.36) L vs. (2.14 ± 0.31) L, (1.57 ± 0.31)L vs. (1.31 ± 0.25) L, there were statistical differences ( P<0.05). After treatment, the levels of serum endotoxin and diamine oxidase in both groups were decreased, and the observation group were lower than those in the control group: (0.22 ± 0.05) kEU/L vs. (0.38 ± 0.10) kEU/L, (5.80 ± 1.00) μg/L vs.(8.16 ± 2.48) μg/L, there were statistical differences ( P<0.05). After treatment, the scores of symptom-related problems, treatment-related problems, worry-related problems, and communication-related problems in the asthma-specific scale of children's quality of life in both groups increased, and scores in the observation group were higher than those in the control group: (86.73 ± 10.59) scores vs. (80.63 ± 13.53) scores, (87.52 ± 14.73) scores vs. (81.35 ± 17.44) scores, (84.36 ± 11.45) scores vs. (78.85 ± 12.42) scores, (87.62 ± 10.86) scores vs.(83.58 ± 12.53) scores, there were statistical differences ( P<0.05). Conclusions:The application of Bifidobacterium triple live bacteria in the adjuvant treatment of children with bronchial asthma accompanied by mycoplasma pneumoniae pneumonia can significantly improve the clinical efficacy, promote the improvement of lung function and intestinal mucosal barrier function of children, and help improve the prognosis of children.
